Salvage therapies appeared to maintain clinical activity among patients with relapsed/refractory multiple myeloma who relapsed after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy, according to study results.
The findings, published in Blood, serve as a benchmark for future clinical trials that aim to improve outcomes among patients who experience disease progression after B-cell maturation antigen (BCMA)-directed CAR-T, investigators noted.
BCMA-directed CAR T-cell therapy has demonstrated efficacy in patients with relapsed/refractory multiple myeloma. However,
